[Myocardial regeneration for heart failure].
We had examined the efficacy of stem cell therapy using tissue engineered sheet technique compared to needle injection. This technique has advantages such as the ability for treatment to large area, and less invasive for host heart such as lethal arrhythmia. In vivo, implantation of autologous myoblast sheet had improved cardiac function of ischemic or dilated cardiomyopathy models using rat, hamster, canine and porcine models. We also showed that myoblast sheets provided various factors inducing angiogenesis, hematopoietic cell recruitment and anti-apoptosis, following anti remodeling. Thus, after approved by IRB of our institution, we have started the clinical trial of myoblast sheet implantation for DCM patients, and assessed the feasibility and efficacy for the first patient. In this patient, any sequelae including arrhythmia have not occurred after implantation, and the cardiac function showed recovery. Thus, stem cell sheet implantation could be safe and eligible as cardiac regeneration therapy.
Sawa
Yoshiki
Y
Department of Cardiovascular Surgery, Graduate School of Medicine, Osaka University.
D000818:Animals; D006224:Cricetinae; D004285:Dogs; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D032446:Myoblasts / Q000637:transplantation; D051381:Rats; D033581:Stem Cell Transplantation / Q000379:methods*; D013552:Swine